Priority Health Launches 2 Cancer Support Solutions with Color Health, Grail
Priority Health partnered with Color Health and Grail to offer self-funded employers virtual cancer navigation, support and multi-cancer early detection beginning in 2027.
Grail’s Galleri Blood Test Falls Short in Large Cancer-Screening Study, Shares Sink 50%
Despite missing statistical significance, Grail said the observation of trending improvement suggests potential for better results with more time, so the company is extending follow up by up to a year. More detailed trial results will be submitted for presentation at the annual meeting of the American Society of Clinical Oncology.
Where Will AI Deployment Benefit Payers the Most?
We are taking a look at how health insurers are using AI, defining success, and managing cybersecurity risks. Give us your opinions by completing our brief, anonymous survey.
Illumina’s European Court Victory Can’t Salvage Grail Acquisition, But It Nullifies Hefty Fine
The European Union’s highest court sided with Illumina, agreeing that the European Commission had no authority to review the acquisition of liquid biopsy company Grail. The ruling comes after Illumina stopped challenging antitrust litigation, opting to instead spin out Grail as a standalone company.
How Can Hospitals Best Leverage Multi-Cancer Screening Tests? Providence Researchers Aim to Find Out
Providence recently launched a study to help learn more about how health systems can use multi-cancer detection tests in clinical care. Three years ago, Providence became the first health system to use Grail’s Galleri test, which screens patients for more than 50 kinds of cancer.
Illumina Spin-Off Now Complete, Grail Sets Out on Its Own on the Public Markets
Liquid biopsy company Grail is now an independent, publicly traded company. While the separation from Illumina ends a protracted antitrust battle, Grail is still in the early stages of a long-term strategy to win regulatory validation and payer coverage for its multi-cancer early detection test.
Illumina’s Antitrust Battles to End With Divestiture of Cancer Test Maker Grail
Illumina has decided against further appeals of U.S. and European antitrust litigation challenging its acquisition of liquid biopsy company Grail. Illumina expects to have terms of the divestiture set by the end of the second quarter of 2024.
presented by
Closing the Quality-Affordability Gap in Workplace Mental Health
In an interview, Kyan Health Co-Founder and Chief Commercial Officer Konstantin Struck discussed how Kyan gives mid-market and enterprise employers access to premium workforce mental healthcare, at a price point that is affordable.
EU Orders Grail Sale; Illumina Continues Appeals But Plans for Multiple Outcomes
European Union regulators ordered Illumina to divest Grail. Illumina is appealing antitrust findings in Europe and the U.S., but the DNA sequencing giant revealed that divesting all or part of Grail is an option even if it wins both legal challenges.
Europe Imposes Maximum Fine on Illumina for Early Grail Acquisition
Illumina must pay a €432 million fine for closing its Grail acquisition before the European Commission finished its inquiry into the tie-up. The penalty is the maximum amount the regulator can impose on a company for breaching European merger rules.
FTC Orders Illumina to Divest Grail, Says Deal Stifles Cancer Test Competition
The Federal Trade Commission has ordered Illumina to divest Grail, the liquid biopsy company it acquired for more than $7 billion. The agency said Illumina’s proposed remedies are insufficient and the tie-up is likely to reduce competition in the R&D and commercialization of new cancer tests.
Carrum Health, GRAIL strike up partnership to offer cancer test to employers
Through the new collaboration, Carrum Health is offering GRAIL's cancer test called Galleri as a benefit option for employers. It is an early-detection test for more than 50 types of cancer.
presented by
Inside an Automated Healthcare Practice: Redesigning Care Around People, Not Paperwork
By reducing administrative burden and redesigning workflows around human needs, it creates space for what matters most: connection between clinicians and patients.
StartUPDATES: New developments from healthcare startups
Check out new developments from Memory Health, Carrum Health, Carmine Therapeutics and Alleva.
Prepping for FDA approval, Grail is partnering with health systems to validate its pan-cancer test
Grail, a company focused on early cancer detection, introduced its test that screens for more than 50 kinds of cancer last year. At AWS' Thursday conference for healthcare and life sciences innovation, the company's chief security officer explained how the company is evaluating the test in clinical trials and preparing to file for its FDA approval.
Illumina’s Grail buyout beats deadline, but legal and regulatory hurdles remain
In closing its Grail acquisition before U.S. and European regulators sign off, Illumina is taking a chance the deal will pass regulatory muster. It’s a potentially pricey gambit, as Illumina could face fines for its early action and there are no assurances that regulators will agree that the deal is not anticompetitive.
Would Illumina’s acquisition of GRAIL constrict the expansion of the liquid biopsy space?
The Federal Trade Commission and the European Union are reviewing the soundness of this acquisition. But if Illumina acquires Grail, the company that it spawned back in January 2016, will it squeeze the nascent liquid biopsy market?
Illumina’s $7.1B Grail buyout is challenged by FTC on competitive grounds
The Federal Trade Commission is opposing Illumina’s proposed $7.1 billion Grail acquisition, arguing that it will reduce competition for multi-cancer early detection tests. Illumina disagrees with the regulator’s position and will oppose the FTC’s challenge.